Released May 2, 2023, after the close
10-Q filed May 4, 2023, 34 days after period end · 0001299130-23-000048
Q1 2023 · 10-Q
Revenue$38.90M$38.90M +17.3% vs Q1 2022+42.2% vs Q4 2022
Net Income-$88.02M-$88.02M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.36-$0.36 N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$9,761,000−31.0%
Operating Income-$91,252,000N/M
Operating Cash Flow-$94,691,000N/M
Free Cash Flowderived-$98,412,000N/M
Margins · derived
Gross margin25.1%−17.6 pt vs Q1 2022
Operating margin-234.6%−0.9 pt vs Q1 2022
Net margin-226.3%+19.4 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $38.90M | $33.17M | $29.00M | $15.60M |
| Net Income | -$88.02M | -$81.50M | -$87.44M | $1.26M |
| EPS Diluted | -$0.36 | -$0.37 | -$0.45 | $0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR